Research programme: central nervous system therapeutics - Schrodinger/Sun Pharma Advanced Research Company
Alternative Names: CNS therapeutics - Schrodinger/Sun Pharma Advanced Research Company; Neurodegeneration drug development programme - Schrodinger/Sun Pharma Advanced Research CompanyLatest Information Update: 28 Jan 2023
At a glance
- Originator Schrodinger; Sun Pharma Advanced Research Company
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for research development in Neurodegenerative-disorders in India
- 28 Jan 2023 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
- 03 Dec 2018 Schrödinger and Sun Pharma Advanced Research Company enter into a research collaboration to discover and develop central nervous system therapeutics for Neurodegenerative disorders